Thursday, Sep 19, 2002
Front Page |
Southern States |
Other States |
Advts: Classifieds | Employment | Obituary |
When contacted, company spokesperson confirmed the development but refused to make any further comment.
Earlier, company was apprehending a delay in the launch of the drug in the wake of GlaxoSmithKline's allegation of stealing the bacteria used in preparation of drug against Novartis and Ranbaxy.
US International Trade Commission has already instituted an investigation into Novartis AG's U.S. marketing of a generic form of the antibiotic as per the information available on agency's website.
Ranbaxy had projected Augmentin sales of 37 million dollars in the US market during 2003. PTI
The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | The Sportstar | Frontline | Home |
Copyright © 2002, The
Hindu. Republication or redissemination of the contents of
this screen are expressly prohibited without the written consent of